JTC Employer Solutions Trustee Ltd Reduces Position in Haleon PLC Sponsored ADR $HLN

JTC Employer Solutions Trustee Ltd cut its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 60.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 282,504 shares of the company’s stock after selling 429,725 shares during the period. JTC Employer Solutions Trustee Ltd’s holdings in Haleon were worth $2,860,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of HLN. Brighton Jones LLC purchased a new stake in shares of Haleon during the fourth quarter valued at $187,000. AQR Capital Management LLC boosted its position in shares of Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after buying an additional 17,720 shares during the last quarter. Focus Partners Wealth boosted its position in shares of Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after buying an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after buying an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC boosted its position in shares of Haleon by 11.6% during the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after buying an additional 2,601 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Down 1.0%

HLN stock opened at $9.22 on Friday. Haleon PLC Sponsored ADR has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The business’s 50-day moving average is $9.56 and its two-hundred day moving average is $9.97. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The company has a market cap of $40.90 billion, a price-to-earnings ratio of 23.65, a P/E/G ratio of 2.12 and a beta of 0.15.

Haleon (NYSE:HLN) last posted its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The firm had revenue of $3.65 billion during the quarter. As a group, analysts forecast that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on HLN shares. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.